Prophylaxis Results Set Stage For Expanded Japan Xofluza Use

Shionogi’s novel single-dose flu drug shows promise in first Phase III results in post-exposure prevention, paving the way for a Japanese filing in this setting and potentially expanding already healthy sales.  

Influenza A H7N9
Xofluza Looks Good In Flu Prophylaxis • Source: Shutterstock

Shionogi & Co. Ltd.'s novel influenza drug Xofluza (baloxavir marboxil) has met its primary endpoint in a Phase III trial which looked at its ability to halt symptoms in people already exposed to the virus, setting the stage for a Japanese approval filing in this setting.

The Phase III, double-blind BLOCKSTONE study in Japan showed a clear prophylactic effect after a single oral dose, which significantly...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia